Design and Evaluation of 3,6-Di(Hetero)Aryl Imidazo[1,2-A]Pyrazines as Inhibitors of Checkpoint and Other Kinases.
Matthews, T.P., Mchardy, T., Klair, S., Boxall, K., Fisher, M., Cherry, M., Allen, C.E., Addison, G.J., Ellard, J., Aherne, G.W., Westwood, I.M., Montfort, R.V., Garrett, M.D., Reader, J.C., Collins, I.(2010) Bioorg.Med.Chem.Lett. 20: 4045
- PubMed: 20561787 
- DOI: 10.1016/j.bmcl.2010.05.096
- Primary Citation of Related Structures:  
- Also Cited By: 2YM8, 2YM7, 2YM6, 2YM5, 2YM4, 2YM3
- PubMed Abstract: 
A range of 3,6-di(hetero)arylimidazo[1,2-a]pyrazine ATP-competitive inhibitors of CHK1 were developed by scaffold hopping from a weakly active screening hit. Efficient synthetic routes for parallel synthesis were developed to prepare analogues with i ...